Docket No: AHP98134 P1 Application No: 10/666851

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: Bodine, Peter

Application No.: 10/666,851 Group Art No.: 1646

Filed: September 19, 2003 Examiner: Xie, Xiaozhen

For: PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING

SECRETED FRIZZLED RELATED PROTEIN

Confirmation No.: 6790 Customer Number: 25291

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

1. <u>Preliminary Statements</u>

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

		art to the subject invention.			
2.			ion of Time of Filing mation Disclosure Statement is filed within three months of the filing date of the application. is filed before the mailing date of a first Office Action on the merits. is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p). is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).		
3.		Certification under 37 CFR 1.97(e) and 1.704(d) The undersigned attorney certifies			
	a.		that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or		

Docket No: AHP98134 P1 Application No: 10/666851

Patent

	b.		that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.			
	C.		certifies that each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.			
4.		Newly Cited Information A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed.				
5.		Previously Cited Information No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120. Prior application is Application Number, filed on of for.				
6.	П а. b.	Concise Explanation Documents cited above which are not in the English Language have been explained in the specification. have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.				
7.	\boxtimes	Fees ⊠	Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00			
	Method of Payment of Fees: Charge Deposit Account No. 01-1425 in the amount of \$180.00					
	Instructions as to Overpayment/Underpayment: Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.					
18 4 41			Joel B. Silver Attorney/Agent for Applicants Reg. No. 53,866			
Wyeth Paten	า t Law	Depar	tment			

Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. (973) 660-6615